Key facts

Below are highlights our performance over the last 12 months:

September 2015

Tuzistra® XR launched in US prescription cough cold market

October 2015

US rights to Moxatag® acquired

October 2015

Three registration batches of CCP-08 successfully manufactured by collaborator Tris and CCP-08 begins 12 month stability testing

December 2015

Successful completion of CCP-07 pivotal single-dose comparative bioavailability study

January 2016

Corvus announced as adenosine receptor antagonist licensee (deal previously announced in February 2015)

April 2016

Successful completion of CCP-08 pivotal single-dose comparative bioavailability study  

April 2016

Successful completion of CCP-07 pivotal multiple-dose comparative bioavailability study

May 2016

Successfully raised £40m (before expenses) in Placing through issue of 80m new Ordinary Shares at a Placing Price of 50p per share

May 2016

Suir Pharma, sole supplier for Moxatag® placed in provisional liquidation

July 2016

€500k milestone received following achievement of new milestone in first oncology drug discovery collaboration with Servier

July 2016

Successful completion of CCP-08 pivotal multiple-dose comparative bioavailability study

Sept 2016

FDA accepted CCP-07 for full review, with PDUFA date of 20 April 2017

 

 

 

Latest News

Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership

Vernalis plc and Servier are pleased to announce that they reinforce their partnership by entering into a new two-year oncology drug discovery collaboration on an undisclosed target.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch